A key element is the introduction of mandatory stockpiles for critical medicines: from 1 July 2024, companies marketing designated critical products in Denmark must maintain safety stocks equivalent to six weeks of expected sales and report inventory levels to the Danish Medicines Agency every two weeks, according to guidance from the Danish Medicines Agency.

In parallel, the Danish government’s 2025–2026 legislative programme includes measures to strengthen security of supply for medical devices by giving the Medicines Agency powers to require reporting on device consumption and stock levels and, where needed, to impose obligations to hold emergency inventories, according to analyses from Bech‑Bruun and Kromann Reumert. Observers argue that Denmark’s proactive implementation of the EU Pharma Package and critical‑medicines rules gives companies earlier clarity on regulatory expectations and can make Danish biotechs and medtechs more attractive as development partners and investment targets than in markets that move more slowly, according to commentaries from EUPerspectives and Pharmadanmark.